Commentary
Video
Author(s):
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
Revisit Every OncLive On Air Episode From May 2024
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer
Revisit the OncLive On Air Episodes From February 2024
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC